Annual Report 2023

• Zhuhai United Laboratories was ranked 63rd in the “Top 500 Manufacturing Enterprises in Guangdong Province for 2022”. JANUARY • The biopharmaceutical sector of The United Laboratories was settled in Hengqin, Zhuhai, and Chairman Mr. Tsoi Hoi Shan, on behalf of the Group, signed a cooperation agreement with the Guangdong-Macao In-Depth Cooperation Zone in Hengqin. • TUL12101 Eye Drops, a class I new drug for dry eye syndrome, was approved for clinical trials. • The United Laboratories’ Amoxicillin Capsules (specification: 0.5g) passed the quality and efficacy consistency evaluation of generic drugs. • The United Laboratories’ Piperacillin Sodium and Tazobactam Sodium for Injection (specification: 4.5g) was listed among the eighth batch of National Centralised Procurement of Pharmaceuticals. • Zhuhai United Laboratories was honored with the title of “the Pioneer of the Pharmaceuticals Industry in Fighting Covid-19 in Guangdong Province”. MARCH • The United Laboratories was ranked 16th in the “Top 100 Chemical and Pharmaceutical Enterprises in China for 2022”. • The United Laboratories was honored with the “County-level Health Development Contribution Award”. JUNE • The United Laboratories’ Piperacillin Sodium and Tazobactam Sodium for Injection (specification: 2.25g) passed the quality and efficacy consistency evaluation of generic drugs. • The cross-border commissioned production to Zhongshan United Laboratories of Vitamin C Effervescent Tablets by Hong Kong United Laboratories was officially launched for production and sold in Mainland China, which was the first cross-border production of pharmaceutical products in the Guangdong-Hong Kong-Macao Greater Bay Area. JULY • The United Laboratories’ Insulin Degludec and Liraglutide Injection was approved for clinical trials. • The United Laboratories’ Semaglutide Injection for weight management indication was approved for clinical trials. APRIL 2 The United Laboratories International Holdings Limited Annual Report 2023 CORPORATE CALENDAR OF 2023